Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: A case report

Journal of Medical Case Reports

Volumn 7, Issue , 2013, Pages

  Ansari, Zia ^a   George, Mathew K ^a  

^a Tamworth Hospital   (Australia)

Author keywords

Metastatic renal cell carcinoma; Sunitinib; Thrombocytopenia

Indexed keywords

IMMUNOGLOBULIN; PREDNISOLONE; STEROID; SUNITINIB; VITAMIN K GROUP; WARFARIN;

AGED; ARTICLE; AUTOIMMUNE THROMBOCYTOPENIA; CANCER CHEMOTHERAPY; CASE REPORT; COMORBIDITY; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPNEA; EPISTAXIS; HUMAN; HUMAN TISSUE; IMMUNE MEDIATED THROMBOCYTOPENIA; INTERNATIONAL NORMALIZED RATIO; KIDNEY CARCINOMA; LUNG BIOPSY; LUNG METASTASIS; MALE; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOPLASTIN TIME;

EID: 84874206408     PISSN: None     EISSN: 17521947     Source Type: Journal    
DOI: 10.1186/1752-1947-7-54     Document Type: Article

References (11)

1. Sunitinib: from rational design to clinical efficacy. Chow Laura QM, Eckhardt SG, J Clin Oncol 2007 25 7 884 896 10.1200/JCO.2006.06.3602 17327610 (Pubitemid 350002890)
2. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand JP, Scigalla P, Raymond E, J Clin Oncol 2006 24 25 35 10.1200/JCO.2005.02.2194 16314617 (Pubitemid 46630490)
3. Drug-induced immune thrombocytopenia. Aster R, Bougie D, N Eng J Med 2007 357 580 587 10.1056/NEJMra066469 (Pubitemid 47236283)
4. Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome. Kapiteijn E, Brand A, Kroep J, Gelderblom H, Ann Oncol 2007 18 10 1745 1747 10.1093/annonc/mdm454 17890216 (Pubitemid 47506266)
5. Tyrosine kinase inhibitor-induced hypothyroidism: incidence, etiology, and management. Brown R, Target Oncol 2011 6 4 217 226 10.1007/s11523-011-0197-2 22101606
6. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma? Sella A, Hercbergs A, Hanovich E, Kovel S, Int J Exp Clin Chemother 2012 58 3 200 205
7. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA, N Eng J Med 2007 356 2 115 124 10.1056/NEJMoa065044 (Pubitemid 46089672)
8. A case of renal cell carcinoma associated with idiopathic thrombocytopenic purpura. Yoshinaga A, Hayashi T, Ohno R, Yoshida S, Ishii N, Terao T, Watanabe T, Yamada T, Hinyokika Kiyo 2005 51 6 377 380 16050475 (Pubitemid 41008468)
9. Renal cell carcinoma and idiopathic thrombocytopenic purpura. Klimberg I, Drylie D, Urology 1984 23 3 293 296 10.1016/S0090-4295(84)90049-9 6538361 (Pubitemid 14164881)
10. Drug-induced immune thrombocytopenic purpura secondary to sunitinib. Trinkaus M, Trudeau M, Callum J, Curr Oncol 2008 15 3 152 154 18596889
11. Sunitinib induced immune thrombocytopenia in patient with metastatic renal cell carcinoma. Tunio M, Ahmad S, Fareed M, AlAsir M, J Solid Tumors 2011 1 2 80 82